Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccine Stockpiling Will Not Encourage Development, Wyeth Exec Says

Executive Summary

Vaccine manufacturers look for market growth potential when selecting projects, Wyeth Exec VP George Siber, MD, said

You may also be interested in...



FDA To Determine Flu Vaccine Suppliers For 2005-2006 Season In January

FDA will decide whether Chiron can produce flu vaccine for next season by Jan. 5, Acting Commissioner Lester Crawford, PhD, said Nov. 18

FDA To Determine Flu Vaccine Suppliers For 2005-2006 Season In January

FDA will decide whether Chiron can produce flu vaccine for next season by Jan. 5, Acting Commissioner Lester Crawford, PhD, said Nov. 18

Sanofi-Aventis Menactra Market Is $3.5 Bil. Over 10 Years, CDC Says

The potential market for Sanofi-Aventis' meningococcal conjugate vaccine Menactra is $3.5 bil. over 10 years, a Centers for Disease Control & Prevention analysis indicates

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel